BACKGROUND: The use of venovenous extra corporeal membrane oxygenation (VV ECMO) for acute respiratory failure (ARF)/acute respiratory (ARDS) has increased since 2009. Specialized units for patients requiring VV ECMO are not standard and patients are often cohorted with other critically ill patients. The purpose of this study was to report the outcome of adult patients admitted in 2015 to the lung rescue unit, which, to our knowledge, is the first intensive care unit in the United States that has been specifically created to provide care for patients requiring VV ECMO. METHODS: Data were collected on all patients admitted to the lung rescue unit on VV ECMO between January 1, 2015, and December 31, 2015. Demographics, medical history, pre-ECMO data, indication for VV ECMO as well as duration of ECMO and survival to decannulation and discharge were recorded. Means (± standard deviation) and medians (interquartile range [IQR]) were reported when appropriate. RESULTS: Forty-nine patients were enrolled. Median age was 48 years (IQR, 32-57). Median PaO2/FIO2 ratio before cannulation was 66 (IQR, 53-86). Median ventilator days before cannulation was 2 (IQR, 1-4). Median time on VV ECMO for all patients was 311 hours (IQR, 203-461). Thirty-eight (78%) patients were successfully decannulated with 35 (71%) patients surviving to hospital discharge. CONCLUSION: The use of VV ECMO for ARF/ARDS is increasing. We have demonstrated that a dedicated multidisciplinary intensive care unit for the purpose of providing standardized care with specialized trained providers can improve survival to discharge for patients that require VV ECMO for ARF/ARDS. LEVEL OF EVIDENCE: Therapeutic, level V.
BACKGROUND: The use of venovenous extra corporeal membrane oxygenation (VV ECMO) for acute respiratory failure (ARF)/acute respiratory (ARDS) has increased since 2009. Specialized units for patients requiring VV ECMO are not standard and patients are often cohorted with other critically ill patients. The purpose of this study was to report the outcome of adult patients admitted in 2015 to the lung rescue unit, which, to our knowledge, is the first intensive care unit in the United States that has been specifically created to provide care for patients requiring VV ECMO. METHODS: Data were collected on all patients admitted to the lung rescue unit on VV ECMO between January 1, 2015, and December 31, 2015. Demographics, medical history, pre-ECMO data, indication for VV ECMO as well as duration of ECMO and survival to decannulation and discharge were recorded. Means (± standard deviation) and medians (interquartile range [IQR]) were reported when appropriate. RESULTS: Forty-nine patients were enrolled. Median age was 48 years (IQR, 32-57). Median PaO2/FIO2 ratio before cannulation was 66 (IQR, 53-86). Median ventilator days before cannulation was 2 (IQR, 1-4). Median time on VV ECMO for all patients was 311 hours (IQR, 203-461). Thirty-eight (78%) patients were successfully decannulated with 35 (71%) patients surviving to hospital discharge. CONCLUSION: The use of VV ECMO for ARF/ARDS is increasing. We have demonstrated that a dedicated multidisciplinary intensive care unit for the purpose of providing standardized care with specialized trained providers can improve survival to discharge for patients that require VV ECMO for ARF/ARDS. LEVEL OF EVIDENCE: Therapeutic, level V.
Authors: Clark G Owyang; Claire Donnat; Daniel Brodie; Hayley B Gershengorn; May Hua; Nida Qadir; Joseph E Tonna Journal: Artif Organs Date: 2022-02-11 Impact factor: 2.663
Authors: Jay Menaker; Ronald B Tesoriero; Ali Tabatabai; Ronald P Rabinowitz; Christopher Cornachione; Terence Lonergan; Katelyn Dolly; Raymond Rector; James V O'Connor; Deborah M Stein; Thomas M Scalea Journal: World J Surg Date: 2018-08 Impact factor: 3.352
Authors: Christopher D Shank; Nicholas J Erickson; David W Miller; Brittany F Lindsey; Beverly C Walters Journal: Neurosurgery Date: 2020-01-01 Impact factor: 4.654
Authors: Sagar Dave; Aakash Shah; Samuel Galvagno; Kristen George; Ashley R Menne; Daniel J Haase; Brian McCormick; Raymond Rector; Siamak Dahi; Ronson J Madathil; Kristopher B Deatrick; Mehrdad Ghoreishi; James S Gammie; David J Kaczorowski; Thomas M Scalea; Jay Menaker; Daniel Herr; Eric Krause; Ali Tabatabai Journal: Membranes (Basel) Date: 2021-04-02
Authors: Elizabeth K Powell; Daniel J Haase; Allison Lankford; Kimberly Boswell; Emily Esposito; Joseph Hamera; Siamak Dahi; Eric Krause; Gregory Bittle; Kristopher B Deatrick; Bree Ann C Young; Samuel M Galvagno; Ali Tabatabai Journal: Perfusion Date: 2022-04-25 Impact factor: 1.581
Authors: Elizabeth K Powell; Allison S Lankford; Mira Ghneim; Joseph Rabin; Daniel J Haase; Siamak Dahi; Kristopher B Deatrick; Eric Krause; Gregory Bittle; Samuel M Galvagno; Thomas Scalea; Ali Tabatabai Journal: Perfusion Date: 2022-09-16 Impact factor: 1.581